SXTPW — 60 DEGREES PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1946563 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 207,898 | 56,798 | -2,271,102 | -2,264,526 | 4,282,694 | 1,022,606 | 1,754,271 |
| Mar 2026 | 162,092 | 76,377 | -2,094,961 | -2,089,214 | 6,763,346 | 3,337,760 | 2,018,867 |
| Dec 2025 | 303,385 | 182,703 | -1,917,351 | -1,438,559 | 5,366,211 | 1,510,065 | 1,986,795 |
| Sep 2025 | 437,602 | -100,088 | -2,325,525 | -2,316,324 | 6,689,344 | 4,115,779 | 2,342,386 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,993,215
Investing CF
$-254,042
Financing CF
$8,110,544
CapEx
$-254,042
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-49,982,329
Inventory
$910,603
Receivables
$335,836
ST Investments
$0
EBIT TTM
$-7,573,838
Pretax Income TTM
$-7,581,242
Interest Exp TTM
$7,404
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,005,471 | -7,758,579 | -7,365,158 | 5,366,211 | 1,986,795 | 3,463,177 | -6,849,022 |
| Dec 2024 | 607,574 | -9,715,181 | -7,947,107 | 5,759,345 | 1,804,339 | 4,035,600 | -5,648,088 |
| Dec 2023 | 253,573 | -5,154,583 | -3,765,702 | 7,783,771 | 2,985,675 | 4,870,134 | -4,542,910 |
| Dec 2022 | 223,208 | -1,750,445 | -6,181,720 | 1,297,206 | 25,446,266 | -23,576,740 | -1,009,980 |
TTM Snapshot
Revenues TTM
$1,004,011
NetIncome TTM
$-7,577,823
OpCashFlow TTM
—
Assets (Latest)
$6,763,346
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
2026-06-11 12:03 · Yahoo
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
2026-05-15 12:42 · Yahoo
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
2026-04-15 12:02 · Yahoo
60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting
2026-10-06 14:44 · Yahoo
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
2026-10-06 12:10 · Yahoo
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-10-02 13:00 · Yahoo
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
2026-10-01 12:03 · Yahoo
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
2026-08-14 19:47 · Yahoo
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
2026-08-11 00:05 · Yahoo
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
2026-08-06 11:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.